What it sells
Alpha-1 antitrypsin gene editing.
Business model breakdown
Trigger: what makes them buy now?
No approved disease-modifying therapy for AATD; only weekly IV augmentation, which does not address liver disease.
Workflow: what inputs become what output?
SERP-01, an in vivo base editing therapy in Phase 1/2, given as a single intravenous administration to restore M-AAT and cut toxic Z-AAT.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-06-29 | — | $230M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.